Codexis, Inc. (NASDAQ:CDXS) has earned an average recommendation of “Buy” from the nine brokerages that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $21.58.

Several brokerages have recently issued reports on CDXS. Zacks Investment Research downgraded Codexis from a “buy” rating to a “hold” rating in a research report on Friday, January 18th. BidaskClub raised Codexis from a “hold” rating to a “buy” rating in a report on Monday, April 1st. ValuEngine raised Codexis from a “buy” rating to a “strong-buy” rating in a report on Monday, April 1st. Craig Hallum boosted their target price on Codexis from $20.00 to $25.00 and gave the stock a “buy” rating in a report on Wednesday, February 27th. Finally, HC Wainwright reissued a “buy” rating and set a $16.50 target price on shares of Codexis in a report on Monday, January 14th.

Shares of CDXS stock opened at $21.27 on Friday. Codexis has a 52 week low of $10.85 and a 52 week high of $23.05. The company has a market capitalization of $1.15 billion, a price-to-earnings ratio of -101.29 and a beta of -0.32.

Codexis (NASDAQ:CDXS) last issued its earnings results on Tuesday, February 26th. The biotechnology company reported ($0.01) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.02) by $0.01. Codexis had a negative return on equity of 24.35% and a negative net margin of 17.95%. The company had revenue of $16.07 million during the quarter, compared to the consensus estimate of $16.62 million. Equities research analysts predict that Codexis will post -0.14 EPS for the current year.

In other Codexis news, CFO Gordon Sangster sold 80,000 shares of the company’s stock in a transaction on Thursday, March 21st. The stock was sold at an average price of $20.88, for a total value of $1,670,400.00. Following the transaction, the chief financial officer now owns 174,453 shares of the company’s stock, valued at $3,642,578.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Dennis P. Wolf sold 9,000 shares of the company’s stock in a transaction on Tuesday, February 26th. The shares were sold at an average price of $21.96, for a total value of $197,640.00. The disclosure for this sale can be found here. Insiders sold 236,987 shares of company stock worth $4,673,191 in the last ninety days. 11.40% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of CDXS. Quantamental Technologies LLC bought a new position in shares of Codexis in the fourth quarter valued at $26,000. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Codexis by 152.0% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,837 shares of the biotechnology company’s stock valued at $47,000 after buying an additional 1,711 shares in the last quarter. Legal & General Group Plc increased its holdings in shares of Codexis by 12.1% in the fourth quarter. Legal & General Group Plc now owns 9,379 shares of the biotechnology company’s stock valued at $157,000 after buying an additional 1,010 shares in the last quarter. United Services Automobile Association bought a new position in shares of Codexis in the third quarter valued at $195,000. Finally, Campbell & CO Investment Adviser LLC bought a new position in shares of Codexis in the fourth quarter valued at $217,000. 85.29% of the stock is currently owned by institutional investors.

About Codexis

Codexis, Inc discovers, develops, and sells protein catalysts. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services.

Further Reading: NASDAQ

Analyst Recommendations for Codexis (NASDAQ:CDXS)

Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.